Summary by Moomoo AI
In 2024, WuXi AppTec's revenue is 0.158 billion yuan, a decrease of 9% year-on-year, with a gross margin of 48.9%. The annual loss narrowed to 0.591 billion yuan, a reduction of 23.1% compared to 0.768 billion yuan in 2023. The loss reduction is mainly due to a 31.6% decrease in R&D spending to 0.283 billion yuan, and a 14.2% decrease in general administrative expenses to 0.12 billion yuan.The company has made multiple advancements in the field of cell immunotherapy, with Benauda® approved for three indications. In August 2024, it was approved for the treatment of adult patients with r/r MCL, becoming the first cell therapy product approved in China for this indication. Additionally, the company completed patient enrollment for clinical trials of Benauda® for second-line LBCL...Show More
Comment(0)
Reason For Report